Marine-derived n-3 fatty acids therapy for stroke

Celia Gabriela Alvarez Campano* (Corresponding Author), Mary J. Macleod, Lorna S. Aucott, Frank Thies

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Downloads (Pure)



With stroke burden increasing, there remains a need to identify therapeutic options that ameliorate the acute insult. There is substantial evidence for a neuroprotective effect of marine-derived n-3 polyunsaturated fatty acids (PUFAs), associated with better functional outcomes in experimental stroke models.


To assess the effects of administration of marine-derived n-3 PUFAs on functional outcomes and dependence in people with stroke.

Our secondary outcomes were vascular-related death, recurrent events, incidence of other type of stroke, adverse events, quality of life, and mood.
Original languageEnglish
Pages (from-to)e314-e315
Number of pages2
Issue number11
Early online date26 Sept 2019
Publication statusPublished - 1 Nov 2019

Bibliographical note

Funding Sources

CG Alvarez Campano’s PhD studies are funded by the Mexican Council for Science and Technology (CONACYT) and the Institute of Innovation and Technology Transfer (I2T2), grant number 457349.


This paper is based on a Cochrane Review published in The Cochrane Library 2019, Issue 6 (see for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, The Cochrane Library should be consulted for the most recent version of the review.


  • stroke
  • treatment
  • functional recovery
  • marine-derived n-3 PUFAs
  • death
  • n-3 fatty acids
  • quality of life
  • incidence
  • neuroprotective effect


Dive into the research topics of 'Marine-derived n-3 fatty acids therapy for stroke'. Together they form a unique fingerprint.

Cite this